|
| Press Releases |
|
 |
|
| Monday, July 29, 2024 |
|
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
| Thursday, July 25, 2024 |
|
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
| Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Malaysia and France Strengthen Defence Industry Ties with Landmark MoU Signing 
Jul 9, 2025 12:08 HKT/SGT
|
|
|
GMG Commencing Sales of G(R) Lubricant and Advancing Regulatory Approvals
Jul 9, 2025 09:00 HKT/SGT
|
|
|
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program
Jul 8, 2025 20:30 JST
|
|
|
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
Jul 8, 2025 9:31 JST
|
|
|
Progress towards potassium-ion batteries
Jul 8, 2025 06:48 HKT/SGT
|
|
|
Kincora Secures Strategic North American Investors and Announces Private Placement
Jul 8, 2025 06:39 HKT/SGT
|
|
|
Small Businesses Embrace Social -- But Could be Missing a Trick in the Age of AI
Jul 8, 2025 06:00 HKT/SGT
|
|
|
15 World Toppers and Near-Perfect Scorers for GIIS Singapore in IBDP 2025 Exams
Jul 7, 2025 12:00 HKT/SGT
|
|
|
Huatai Foundation Supports NbS Summer School, Convening Global Youth to Tackle Ecological Conservation
Jul 7, 2025 10:44 HKT/SGT
|
|
|
MHI Awarded Contract for Basic Design of Japan's Largest CO2 Capture Plant at Hokkaido Electric Power's Tomato-Atsuma Power Station
Jul 7, 2025 11:15 JST
|
|
|
Fujitsu's high-precision skeleton recognition AI adopted to enhance figure skating athlete training
Jul 5, 2025 13:40 JST
|
|
|
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
Jul 4, 2025 18:59 HKT/SGT
|
|
|
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 4, 2025 16:20 JST
|
|
|
MHIET Launches 450kW Gas Cogeneration System Capable of Hydrogen Co-Firing
Jul 4, 2025 15:13 JST
|
|
|
INVEST FAIR Malaysia 2025 Spotlights Investor Trends, Multi-Asset Literacy, and Tech-Driven Platforms
Jul 4, 2025 13:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
